Parallel Advisors’s Arbutus Biopharma ABUS Stock Holding History

Parallel Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.97K	Hold	1,039	–	–	﹤0.01%	3372
2026 Q2	$4.99K	Hold	1,039	–	–	﹤0.01%	3210
2026 Q1	$4.68K	Sell	1,039 -165	-14%	-$721	﹤0.01%	3054
2025 Q4	$5.79K	Hold	1,204	–	–	﹤0.01%	2794
2025 Q3	$5.47K	Sell	1,204 -116	-9%	-$426	﹤0.01%	2744
2025 Q2	$4.08K	Buy	1,320 +489	+59%	+$1.62K	﹤0.01%	2809
2025 Q1	$2.9K	Hold	831	–	–	﹤0.01%	2866
2024 Q4	$2.72K	Hold	831	–	–	﹤0.01%	2862
2024 Q3	$3.2K	Hold	831	–	–	﹤0.01%	2761
2024 Q2	$2.57K	Buy	831 +281	+51%	+$843	﹤0.01%	2734
2024 Q1	$1.42K	Hold	550	–	–	﹤0.01%	2873
2023 Q4	$1.38K	Hold	550	–	–	﹤0.01%	2876
2023 Q3	$1.12K	Hold	550	–	–	﹤0.01%	2957
2023 Q2	$1.26K	Sell	550 -122	-18%	-$318	﹤0.01%	2873
2023 Q1	$2.04K	Buy	672 +122	+22%	+$344	﹤0.01%	2770
2022 Q4	$1.28K	Hold	550	–	–	﹤0.01%	2837
2022 Q3	$1K	Sell	550 -169	-24%	-$398	﹤0.01%	2827
2022 Q2	$2K	Buy	719 +169	+31%	+$433	﹤0.01%	2521
2022 Q1	$2K	Hold	550	–	–	﹤0.01%	2535
2021 Q4	$2K	Hold	550	–	–	﹤0.01%	2644
2021 Q3	$2K	Hold	550	–	–	﹤0.01%	2630
2021 Q2	$2K	Hold	550	–	–	﹤0.01%	2516
2021 Q1	$2K	Hold	550	–	–	﹤0.01%	2433
2020 Q4	$2K	Hold	550	–	–	﹤0.01%	2254
2020 Q3	$2K	Buy	+550	New	+$1.67K	﹤0.01%	2253

Other funds holding ABUS

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Carrera Capital Advisors Troy, Michigan $705M AUM 12.86% 1-Year Est. Return

Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Financiere des Professionnels Montreal, Quebec, Canada $1.75B AUM 28.24% 1-Year Est. Return

KAM

Kazazian Asset Management Fort Lauderdale, Florida $115M AUM 9.41% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Parallel Advisors's ABUS Position: Q3 2026 in Review

Parallel Advisors held its Arbutus Biopharma (ABUS) position steady in Q3 2026 at 1,039 shares worth $4.97K. The position accounts for ﹤0.01% of the portfolio, ranked #3372.

Parallel Advisors first reported a position in ABUS in Q3 2020 and has held it in 25 quarters since. The position peaked at $5.79K in Q4 2025. 46 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

Parallel Advisors held 1,039 shares of Arbutus Biopharma worth $4.97K as of Q3 2026.
Parallel Advisors left its Arbutus Biopharma share count unchanged in Q3 2026.
Arbutus Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3372 holding.
Parallel Advisors first reported a position in Arbutus Biopharma in Q3 2020 and has held it in 25 quarters since.
Parallel Advisors's Arbutus Biopharma position peaked at $5.79K in Q4 2025.
46 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.